Return to Article Details
Role of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitor Therapy in treatment of Patients with Polycystic Ovary Syndrome: A systemic Review of Metabolic and Cardiovascular Outcomes
Download
Download PDF